Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 712 results
Filters: Author is Gulick, Roy M  [Clear All Filters]
Found 712 results.

Adult

Shikuma CM, Yang Y, Glesby MJ, et al. "Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)." J. Acquir. Immune Defic. Syndr.. 2007;44(5):540-50.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Mollan KR, Tierney C, Hellwege JN, et al. "Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants." J. Infect. Dis.. 2017;216(5):554-564.
Weinberg A, Bosch R, Bennett K, et al. "Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS." J. Acquir. Immune Defic. Syndr.. 2014;66(1):25-32.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. "Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects." J. Infect. Dis.. 2008;197(6):867-70.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Gupta SK, Komarow L, Gulick RM, et al. "Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects." J. Infect. Dis.. 2009;200(4):614-8.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Mollan KR, Smurzynski M, Eron JJ, et al. "Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data." Ann. Intern. Med.. 2014;161(1):1-10.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Morris BL, Scott CA, Wilkin TJ, et al. "Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development." HIV Clin Trials. 2012;13(1):1-10.

Pages